The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration

• Main Authors: Linda A. Villani (Author), Brennan K. Smith (Author), Katarina Marcinko (Author), Rebecca J. Ford (Author), Lindsay A. Broadfield (Author), Alex E. Green (Author), Vanessa P. Houde (Author), Paola Muti (Author), Theodoros Tsakiridis (Author), Gregory R. Steinberg (Author)
• Format: Book
• Published: Elsevier, 2016-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: The sodium-glucose transporter 2 (SGLT2) inhibitors Canagliflozin and Dapagliflozin are recently approved medications for type 2 diabetes. Recent studies indicate that SGLT2 inhibitors may inhibit the growth of some cancer cells but the mechanism(s) remain unclear. Methods: Cellular proli...